Skip to main content
Premium Trial:

Request an Annual Quote

London Genetics, Astrimmune to Develop Biomarkers for Pancreatic Cancer Vaccine

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – London Genetics and Astrimmune today announced a collaboration to identify predictive biomarkers for a pancreatic cancer vaccine being developed by Astrimmune.

The collaboration, being supported with a grant from the UK East Midlands Development Agency, will seek to identify biomarkers predictive of clinical response.

In a statement, the two firms said that Astrimmune's vaccine induces antibody production against gastrin, a hormone which stimulates the growth of many types of gastrointestinal cancer. Different response rates have been observed in clinical trials of gastrin-blocking products, "and there is a clear need for biomarkers to help identify those patients mostly likely to benefit from Astrimmune's product," they said.

Financial and other terms of the deal were not disclosed.

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.